Gestational Diabetes and the Maternal Microbiome: The Role of Probiotics in Metabolic and Immune Modulation

Gestational diabetes mellitus (GDM) is one of the most prevalent metabolic disorders during pregnancy, affecting approximately 14% of pregnancies worldwide and posing significant risks to both maternal and fetal health. While conventional management strategies such as dietary interventions and insulin therapy remain essential, they often fail to address the multifactorial nature of the condition, which includes systemic inflammation, immune dysregulation, and alterations in the gut microbiota. In recent years, probiotics have emerged as promising adjunctive interventions, offering multi-targeted mechanisms that include improving intestinal barrier integrity, modulating immune responses, producing short-chain fatty acids, and influencing incretin secretion. This review synthesizes the latest evidence from clinical trials assessing probiotic supplementation in women with GDM, with a particular focus on multistrain formulations combining <i>Lactobacillus</i> and <i>Bifidobacterium</i> species. Results consistently show modest but clinically meaningful improvements in fasting blood glucose and inflammatory biomarkers, alongside a favorable safety profile. Limitations in the existing literature, such as small sample sizes, heterogeneous protocols, and short intervention durations, underscore the need for larger, standardized, and longer-term studies. Probiotics represent more than a glycemic control tool; they embody a conceptual shift toward biologically integrated, low-risk strategies that align with the physiology of pregnancy and the ecology of the maternal microbiome, with the potential to improve both immediate and long-term health outcomes for mothers and their children.